Celcuity Inc. Common Stock (CELC)

About CELC

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients wi…

Sector

Health Care

Industry

Medical Specialities

Employees

155

Website

www.celcuity.com/

Fundamentals

1-day range

$88.23$92.48

Market cap

$4.28B

P/E (trailing)

—

P/E (forward)

-1105.50

EPS (trailing)

$-3.90

Dividend yield

—

Beta

0.09

Avg. volume

1.51M

Forecasts

11 analyst ratings

Celcuity Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• CELC

  Celcuity Inc. Common Stock

  $88.46

  ▼ 5.13%
  Market cap $4.28BP/E —
  $44.42$151.02
• CAI

  Caris Life Sciences Inc. Common Stock

  $25.64

  ▼ 2.81%
  Market cap $4.61BP/E 59.62
  $14.19$39.18
• VCYT

  Veracyte Inc. Common Stock

  $43.36

  ▼ 4.19%
  Market cap $3.58BP/E 29.24
  $28.25$60.91
• ALHC

  Alignment Healthcare Inc. Common Stock

  $13.62

  ▲ 0.44%
  Market cap $3.02BP/E 68.60
  $12.7$25.12
• GRAL

  GRAIL Inc. Common Stock

  $79.94

  ▼ 3.10%
  Market cap $3.02BP/E —
  $30.82$118.84
• CDNA

  CareDx Inc. Common Stock

  $49.73

  ▼ 5.02%
  Market cap $2.48BP/E 22.08
  $12.37$53.67
• BLLN

  BillionToOne Inc. Class A Common Stock

  $93.27

  ▼ 1.98%
  Market cap $6.32BP/E 117.67
  $61.96$150.44

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Kazia Therapeutics: Upcoming Data May Validate Best-In-Class Potential Of Paxalisib
  SeekingAlpha · 8/27/2026
• Celcuity Files Supplemental New Drug Application To FDA For REVTORPYK To Treat Breast Cancer
  benzinga · 8/26/2026
• Celcuity Files Supplemental New Drug Application To FDA For REVTORPYK To Treat Breast Cancer
  Benzinga · 8/26/2026
• Guggenheim Maintains Buy on Celcuity, Raises Price Target to $175
  Benzinga · 8/17/2026
• Citizens Reiterates Market Outperform on Celcuity, Maintains $177 Price Target
  Benzinga · 8/17/2026
• HC Wainwright & Co. Reiterates Buy on Celcuity, Maintains $155 Price Target
  Benzinga · 8/14/2026
• Celcuity: REVTORPYK Is Now A Commercial Story
  SeekingAlpha · 8/14/2026
• Celcuity Analysts Slash Their Forecasts After Q2 Loss
  Benzinga · 8/14/2026
• Stifel Maintains Buy on Celcuity, Lowers Price Target to $150
  Benzinga · 8/14/2026

• BAKER BROS. ADVISORS LP · July 14, 2026 · Sale

  2.84M @ $102.5
• BAKER BROS. ADVISORS LP · July 14, 2026 · Sale

  261.4K @ $102.5
• Murphy Polly A. · June 10, 2026 · Gift

  14.0K
• Buller Richard E · June 10, 2026 · Gift

  12.5K
• Murphy Polly A. · June 5, 2026 · Grant

  1.5K
• ROMP CHARLES R · June 5, 2026 · Grant

  1.5K
• Furcht Leo · June 5, 2026 · Grant

  1.5K
• Buller Richard E · June 5, 2026 · Grant

  1.5K
• Dalvey David · June 5, 2026 · Grant

  1.5K
• Richard Nigon · June 5, 2026 · Grant

  1.5K
• Laing Lance G. · June 2, 2026 · Option Exercise

  1.0K @ $9.89
• Buller Richard E · May 19, 2026 · Gift

  1.0K
• Buller Richard E · May 4, 2026 · Option Exercise

  9.0K @ $5.1
• Buller Richard E · May 4, 2026 · Sale

  365 @ $143.24
• Buller Richard E · May 4, 2026 · Sale

  2.8K @ $142.04

Institutional Ownership

March 31, 2026

Total shares held

50.76M

Total value held

$5.55B

Institutional holders

271